Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma

Share :
Published: 30 Apr 2020
Views: 1080
Prof Alain Algazi -University of California San Francisco, San Francisco, USA

Prof Alain Algazi speaks to ecancer about results from the SWOG S1320 study, which used intermittent dabrafenib and trametinib in patients with BRAF mutated melanoma. This discussion covers developments that were presented at the AACR Virtual Meeting 2020, which was moved online due to the COVID-19 pandemic.

Prof Algazi explains that pre-clinical research indicated that intermittent dosing compared to continuous dosing might overcome the problem of drug resistance in these patients. However, to their surprise, the study found that there was improved progression-free survival in patients receiving continuous dosing, although overall-survival was similar.

He goes on to discuss how they are planning to follow-up this study and what can be learned from their results in terms of human vs mouse trials.

Read more about the study here